A DB, Randomized, Placebo Controlled, Parallel Group Study to Qualify a Biomarker Algorithm for Risk of Developing MCI due to AD and to Test the S&E of Pioglitazone (AD-4833 SR 0.8 mg QD) Delay Onset of MCI due AD in Cognitively Normal Subjects.
Clinical Trial Grant
Administered By
Neurology
Awarded By
Takeda Pharmaceuticals North America Inc.
Start Date
July 1, 2013
End Date
March 26, 2019
Administered By
Neurology
Awarded By
Takeda Pharmaceuticals North America Inc.
Start Date
July 1, 2013
End Date
March 26, 2019